Key result
Newer oral anticoagulants provide stable anticoagulation at a fixed dose without laboratory monitoring, showing improvements in safety and efficacy over conventional Vitamin K antagonists.
Why the study?
Conventional anticoagulants have limitations including wide dose-response variations, delayed onset and offset, narrow therapeutic ranges, and need for frequent monitoring, prompting the review of FDA-approved newer oral anticoagulants.
Do newer oral anticoagulants offer improved safety and efficacy compared to conventional anticoagulants in patients requiring anticoagulation?
Comparison
Newer oral anticoagulants vs conventional anticoagulants
Design
Review
Authors
Loading...
May support convenient anticoagulation without monitoring; hypothesis-generating from Level 5 review and needs prospective validation.
Do newer oral anticoagulants offer improved safety and efficacy compared to conventional anticoagulants in patients requiring anticoagulation?
Newer oral anticoagulants provide a more convenient, stable therapeutic regimen with improved safety and efficacy compared to conventional anticoagulants, without the need for routine laboratory monitoring.
Morries et al. (2020) conducted a review in Thromboembolism. Newer Oral Anticoagulants vs. Conventional anticoagulants (e.g., Vitamin K antagonists, heparin) was evaluated. Newer oral anticoagulants provide stable anticoagulation at a fixed dose without laboratory monitoring, showing improvements in safety and efficacy over conventional Vitamin K antagonists.